Source: Value in Health. Conference titles: ISPOR Europe. Unidade: FCF
Subjects: DOENÇAS RARAS, MEDICAMENTO
ABNT
BIGLIA, Luiza Vasconcelos et al. Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil. Value in Health. Amsterdam: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.jval.2023.09.1783. Acesso em: 22 ago. 2024. , 2023APA
Biglia, L. V., Felippini, A., Ribeiro, T. B., Lima, T. D. M., & Aguiar, P. M. (2023). Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil. Value in Health. Amsterdam: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. doi:10.1016/j.jval.2023.09.1783NLM
Biglia LV, Felippini A, Ribeiro TB, Lima TDM, Aguiar PM. Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil [Internet]. Value in Health. 2023 ; 26( 12): S337.[citado 2024 ago. 22 ] Available from: https://doi.org/10.1016/j.jval.2023.09.1783Vancouver
Biglia LV, Felippini A, Ribeiro TB, Lima TDM, Aguiar PM. Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil [Internet]. Value in Health. 2023 ; 26( 12): S337.[citado 2024 ago. 22 ] Available from: https://doi.org/10.1016/j.jval.2023.09.1783